SAN DIEGO


,


Dec. 29, 2022


/PRNewswire/ — Evofem Biosciences, Inc. (OTCQB: EVFM) today announced that it has been granted additional time by the OTC Markets Group to file its Quarterly Report on Form 10-Q for the quarter ended

September 30, 2022

(the “10-Q”).  Previously, the OTC Markets Group provided until

December 29, 2022

to file the 10-Q . The extended deadline is now

January 6, 2023

.

About Evofem


Evofem Biosciences, Inc., is developing and commercializing innovative products to address unmet needs in women’s sexual and reproductive health. The Company’s first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at


phexxi.com


and


evofem.com


.

Phexxi

^®

is a registered trademark of Evofem Biosciences, Inc.

About Phexxi


Phexxi is an on-demand method of birth control used to prevent pregnancy. Phexxi is not effective when used after sex.  For more information about Phexxi, talk to your healthcare provider and see full Product Information at

www.phexxi.com

.

Contacts



Investors:



Amy Raskopf


SVP, Investor Relations

Evofem Biosciences, Inc.


[email protected]


(917) 673-5775

Media:



[email protected]

View original content to download multimedia:

https://www.prnewswire.com/news-releases/otc-markets-group-grants-evofem-additional-time-to-file-quarterly-report-on-form-10-q-for-the-quarter-ended-september-30-2022-301711204.html

SOURCE Evofem Biosciences, Inc.